Special Issue

Update in Lung Cancer Molecular Pathology: Technological Advances and Clinical Practice

Message from the Guest Editors

Molecular pathology has dramatically changed the landscape of diagnosis and therapy for lung cancer patients. In the few last years, the implementation of predictive molecular pathology in clinical settings has led to a remarkable improvement in terms of progression-free survival and overall survival, in particular, for non-small-cell lung cancer patients demonstrating mutations in clinically relevant biomarkers, such as EGFR, BRAF, ALK, ROS1, RET, and NTRK or strong PD – L1 expression. This Special Issue entitled "Update in Lung Cancer Molecular Pathology: Technological Advances and Clinical Practice" will address the new insights into next-generation technologies, useful for detecting druggable targets either in usual or rare NSCLC histotypes and to promote more effective management of lung cancer patients.

Guest Editors

Dr. Paolo Graziano

Unit of Pathology, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy

Dr. Giulio Rossi

Operative Unit of Pathologic Anatomy, Azienda USL della, Romagna, Hospital S. Maria delle Croci, Viale Randi 5, Ravenna, Italy

Deadline for manuscript submissions

closed (31 December 2022)

Cancers

mdpi.com/journal/cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)